Stephanie J. Schwartz


Stephanie J. Schwartz


Stephanie Schwartz is an associate with Foley & Lardner LLP, based in the firm’s Boston office, where she is a member of the Healthcare Practice.

In 2018, Stephanie was selected for the Mayo-Foley Health Law Fellowship, consisting of summer internships with the Mayo Clinic Legal Department in Rochester, Minnesota (2018) and Foley (2019). During this time, she assisted attorneys at both Mayo Clinic and Foley with a broad range of regulatory compliance and transactional matters.

Prior to Foley, Stephanie was a compliance consultant and HIPAA compliance analyst for a management services organization in Miami, Florida. In her position, she advised and trained a multi-specialty group practice of over 500 physicians on compliance practices, and she prepared and reviewed policies, documents and compliance-related communications.

28 September 2023 In the News

Foley Attorneys Author U.S. Chapter in Seventh Edition of The Healthcare Law Review

26 July 2023 Health Care Law Today

CMS Proposes Remedy for 340B-Acquired Drug Payment Policy for CY 2018-2022

Along with its calendar year 2024 Medicare Outpatient Prospective Payment System proposed rule, the Centers for Medicare & Medicaid Services have also published the long-awaited proposal to remediate the violations that arose from Medicare’s rate cuts for 340B drugs dispensed by 340B hospitals from January 1, 2018 through September 27, 2022.
18 July 2023 Deals and Wins

Foley Serves as Legal Adviser to Thirty Madison in Strategic Acquisition of The Pill Club Assets

Foley & Lardner LLP served as legal adviser to Thirty Madison, a leading chronic care management platform, in its strategic acquisition of assets from The Pill Club.
04 April 2023 Deals and Wins

Foley Represents Transcarent in Acquiring Part of 98point6 for $100M

Foley & Lardner LLP represented health and care experience company Transcarent in acquiring AI-powered virtual care platform capabilities and the care business of 98point6 in a deal worth up to $100 million.
30 March 2023 Manufacturing Industry Advisor

The Future of the 340B Program: 2023 Key Decisions

Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program, which provides discounts on outpatient drugs for certain health care providers, referred to as “covered entities.”
18 July 2022 Blogs

340B Rate Cuts Reversed by CMS for 2023

The Centers for Medicare and Medicaid Services (CMS) has announced that it “fully expects” to reverse Medicare Part B rate cuts for separately payable drugs acquired through the 340B Drug Pricing Program, resulting in an estimated additional $1.96 billion for 340B hospitals.